UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624

2018

Volltextzugriff (PDF)

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

The New England journal of medicine, 2013-11, Vol.369 (22), p.2093-2104

2013

Volltextzugriff (PDF)

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.687-694

2011

Volltextzugriff (PDF)

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

European heart journal, 2014-06, Vol.35 (22), p.1457-1465

2014

Volltextzugriff (PDF)

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of cardiovascular pharmacology, 2013-08, Vol.62 (2), p.212-221

2013

Volltextzugriff (PDF)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2022-07, Vol.6 (5), p.e12748-n/a, Article e12748

2022

Volltextzugriff (PDF)

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Research and practice in thrombosis and haemostasis, 2021-07, Vol.5 (5), p.e12566-n/a, Article e12566

2021

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-10, Vol.13 (5), p.331-342

2013

Volltextzugriff (PDF)

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

European heart journal, 2019-05, Vol.40 (19), p.1541-1550

2019

Volltextzugriff (PDF)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

European heart journal, 2023-04, Vol.44 (14), p.1231-1244

2023

Volltextzugriff (PDF)

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5675-5676

2022

Volltextzugriff (PDF)

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.966-978

2013

Volltextzugriff (PDF)

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

The American heart journal, 2018-11, Vol.205, p.63-69

2018

Volltextzugriff (PDF)

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension (Dallas, Tex. 1979), 2019-09, Vol.74 (3), p.597-605

2019

Volltextzugriff (PDF)

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335

2012

Volltextzugriff (PDF)

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Thrombosis research, 2020-11, Vol.195, p.209-214

2020

Volltextzugriff (PDF)

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate-Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials

Journal of pain and symptom management, 2005-06, Vol.29 (6), p.584-594

2005

Volltextzugriff (PDF)

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335-341

2012

Volltextzugriff (PDF)

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2929-2940

2023

Volltextzugriff (PDF)

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Journal of thrombosis and haemostasis, 2021-11, Vol.19 (11), p.2801-2813

2021

Volltextzugriff (PDF)

TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial

Journal of the American College of Cardiology, 2017-10, Vol.70 (18), p.B163-B163

2017

Volltextzugriff (PDF)

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Thrombosis research, 2015-10, Vol.136 (4), p.825-831

2015

Volltextzugriff (PDF)

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

International journal of cardiology, 2018-04, Vol.257, p.102-107

2018

Volltextzugriff (PDF)

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A2095-A2095

2014

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate-Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Aktive Filter

Suchergebnisse filtern